231 results on '"Viallard, Jean-Francois"'
Search Results
52. Erythème étoilé réactionnel au bortezomib
53. Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study
54. Risk Factors of Neonatal Immune Thrombocytopenia in Pregnant Women Previously Diagnosed with ITP: Results from a French Nationwide Prospective Study
55. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
56. Severe prolonged red blood cell aplasia arid thrombocytopenia induced by parvovirus B19 infection in a patient with sarcoidosis. (Brief Report)
57. La thrombocytose : un effet secondaire méconnu de l’héparinothérapie
58. CD8 +HLA-DR + T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation
59. First description of an IgM monoclonal antibody causing αIIbβ3 integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia
60. Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry
61. Efficacy and safety of rituximab for autoimmune neutropenia: a French case series and literature review
62. Rôle des cellules dendritiques et de l'interféron alpha dans le lupus érythémateux systémique
63. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome
64. Tuberculous Meningitis
65. Granulomatous Disease in Common Variable Immunodeficiency
66. Reversible myelofibrosis induced by tuberculosis. (Brief Report)
67. Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome
68. Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
69. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance
70. Renal Intravascular Large B-cell Lymphoma: A Case Report and Review of the Literature
71. Bone-marrow fibrin-ring granuloma
72. Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients
73. Multicentric Hyaline-Vascular Castleman Disease: The Missing Link?
74. Evaluation of the Efficacy and Safety during Treatment with TPO-Ras in 40 SLE-ITP and APS-ITP Patients
75. Autoimmune Cytopenia Associated with Indolent B-Cell Clones: A Large Multicentric Cohort Study
76. Whole Exome Sequencing of Patients with Adult-Onset Evans Syndrome: A Cohort of 80 Patients
77. Efficacy and Safety of Dapsone in Primary Immune Thrombocytopenia. Results of a Randomized, Placebo-Controlled Multicenter Trial and of a Single-Arm, Emulated Trial in the Prospective, Multicenter Carmen-France Registry
78. HLH-JAKthe First Open-Label, Phase II Study Evaluating Anti-JAK1 Itacitinib, for Non Severe HLH in Adults
79. Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia
80. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
81. A Final Analysis of a Phase 2, Single-Arm Study of Platelet (Plt) Responses and Remission Rates in Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim
82. Secondary hyperaldosteronism in a patient with polyarteritis nodosa and renal artery aneurysms
83. Hyperaldostéronisme secondaire au cours d’ une périartérite noueuse avec anévrismes des artères rénales
84. The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
85. An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim
86. A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists
87. Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the “real-life” : Result of the French Experience in 72 Adults.
88. Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.
89. Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).
90. Immune (Idiopathic) Thrombocytopenic Purpura (ITP): Treatment Pattern and Splenectomy Rate from a Multinational Prospective Observational Study
91. Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
92. Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Interim Results from an Open-Label Study of AMG 531.
93. Use of Human Immunoglobulins in Secondary Immunodeficiencies Associated with Hematological Malignancy in Real-Life Practice: Which Patients, Which Treatment?
94. Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions
95. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases
96. Flow Cytometry Study of Human Cyclin B1 and Cyclin E Expression in Leukemic Cell Lines: Cell Cycle Kinetics and Cell Localization
97. Platelet-associated CD154 in immune thrombocytopenic purpura
98. FCGR3A V/F 158 Polymorphism Is Not Associated with Response to Rituximab in adult's Immune Thrombocytopenia
99. Intrinsic Impairment of Platelet Production in Persistent/Chronic ITP
100. Chronic eosinophilic pneumonia presenting with pericarditis and ventricular wall hypertrophy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.